Literature DB >> 7623772

Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives.

P De Isabella1, M Palumbo, C Sissi, G Capranico, N Carenini, E Menta, A Oliva, S Spinelli, A P Krapcho, F C Giuliani.   

Abstract

The cytotoxic activity of mitoxantrone and related anthracenediones has been ascribed to the ability of these compounds to interfere with DNA topoisomerase II function, resulting in DNA cleavage stimulation. The molecular details of enzyme inhibition by these intercalating agents remain to be defined. In an attempt to identify the structural determinants for optimal activity, the molecular and cellular effects of a series of heteroanalogues bearing different side-chains were examined in relation to the physico-chemical and DNA binding properties of these compounds. The results indicated that substitution of a pyridine ring for the dihydroxyphenylene ring in the planar chromophore caused a marked reduction of cytotoxic activity and of the ability to stimulate topoisomerase II-mediated DNA damage in intact cells and with simian virus 40 DNA in vitro. Although all tested derivatives were shown to intercalate into DNA, their DNA binding affinities were appreciably lower than that of mitoxantrone. The behavior of 2-aza derivatives more closely resembled that of ametantrone, suggesting that the potency of agents of this class is influenced more by the presence of hydroxyl groups than by the phenylene ring. The observation that a dramatic reduction (or loss) of the ability of aza derivatives to stimulate DNA cleavage is associated with a marked reduction of cytotoxic potency supports a primary role of topoisomerase II-mediated effects in the mechanism of action of the effective agents of this class. Because appreciable cytotoxic activity and significant in vivo antitumor efficacy are retained by compounds inactive (or poorly active) in inhibition of topoisomerase II, these results are consistent with multiple effects of anthracenediones at the cellular level.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7623772

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  11 in total

1.  A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding.

Authors:  Guohua An; Marilyn E Morris
Journal:  AAPS J       Date:  2012-03-27       Impact factor: 4.009

2.  An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells.

Authors:  Oula C Mansour; Abraham Nudelman; Ada Rephaeli; Don R Phillips; Suzanne M Cutts; Benny J Evison
Journal:  Cancer Chemother Pharmacol       Date:  2022-04-23       Impact factor: 3.288

3.  Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly.

Authors:  Liang Deng; Peihong Dai; Anthony Ciro; Donald F Smee; Hakim Djaballah; Stewart Shuman
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

4.  Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.

Authors:  Brian B Hasinoff; Xing Wu; Daywin Patel; Ragu Kanagasabai; Soumendrakrishna Karmahapatra; Jack C Yalowich
Journal:  J Pharmacol Exp Ther       Date:  2015-12-11       Impact factor: 4.030

5.  Anacardic acid enhances the anticancer activity of liposomal mitoxantrone towards melanoma cell lines - in vitro studies.

Authors:  Mateusz Legut; Dominik Lipka; Nina Filipczak; Adriana Piwoni; Arkadiusz Kozubek; Jerzy Gubernator
Journal:  Int J Nanomedicine       Date:  2014-01-23

Review 6.  Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.

Authors:  Stefano Volpetti; Francesco Zaja; Renato Fanin
Journal:  Onco Targets Ther       Date:  2014-05-29       Impact factor: 4.147

7.  Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions.

Authors:  Neil Beeharry; Andrea Ghelli Luserna Di Rora; Mitchell R Smith; Timothy J Yen
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

8.  CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity.

Authors:  Benny J Evison; Rebecca A Bilardi; Francis C K Chiu; Gabriella Pezzoni; Don R Phillips; Suzanne M Cutts
Journal:  Nucleic Acids Res       Date:  2009-08-31       Impact factor: 16.971

9.  Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent.

Authors:  Ben J Evison; Oula C Mansour; Ernesto Menta; Don R Phillips; Suzanne M Cutts
Journal:  Nucleic Acids Res       Date:  2007-05-05       Impact factor: 16.971

10.  On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs.

Authors:  Chyuan-Chuan Wu; Yi-Ching Li; Ying-Ren Wang; Tsai-Kun Li; Nei-Li Chan
Journal:  Nucleic Acids Res       Date:  2013-09-14       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.